# TiNivo (NCT03136627)

> Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

No report yet. It can be ordered.

- Drugs tested: tivozanib plus nivolumab
- Indication: metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03136627
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: AVEO Pharmaceuticals, Inc.
- Conditions: Carcinoma, Renal Cell
- Interventions: Tivozanib; Nivolumab
- Enrollment: 28
- Primary outcome: Maximum Tolerated Dose (MTD) of tivozanib administered orally in combination with Nivolumab in subjects with advanced renal cell carcinoma.

## Indexed commentary on TiNivo so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X
- 4 YouTube videos
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tinivo-nct03136627

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03136627", "email": "<work email>"}; the inbox owner confirms by the emailed link.